Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Repligen (RGEN) Tops Q3 EPS by 12c, Revenues Beat; Offers FY20 EPS/Revenue Guidance Above Consensus
November 5, 2020 7:47 AM ESTRepligen (NASDAQ: RGEN) reported Q3 EPS of $0.40, $0.12 better than the analyst estimate of $0.28. Revenue for the quarter came in at $94.1 million versus the consensus estimate of $86.45 million.
Reports record quarterly revenue of $94.1 million with strong margin expansionOverall revenue grew 35% year-over-year, with organic growth of 31%Raises revenue guidance to $348-$352 million and overall revenue growth to 29%-30% for full year 2020, representing 23%-24% organic growthCompletes acquisition of Non-Metallic Solutions and announces agreement to acquire bioprocess systems innovator ARTeSYN BiosolutionsTony J. Hunt, President and Chief Executive Officer said, We are... More
